The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

A method for reducing a contaminating DNA content of a preparation containing AAV capsids and contaminating DNA, comprising the steps of a) Performing an extraction of DNA with a solid phase bearing positive charges at its surface said solid phase is contacted with the preparation at a pH of 7.0±1.0, and a salt concentration of 10 mM to 200 mM yielding a first fraction, (b) Diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction, (c) Treating the second fraction with DNase, (d) Diafiltering the DNase treated second fraction obtained by step c) by a second tangential flow, (e) filtration to a buffer with pH of 7.0±1.0, and a salt concentration of 10 mM to 20 mM to yield a third fraction, and optionally (f) Concentrating the third fraction by tangential flow filtration before supplemental chromatography.

A method for reducing a contaminating DNA content of a preparation containing AAV capsids and contaminating DNA, comprising the steps of a) Performing an extraction of DNA with a solid phase bearing positive charges at its surface said solid phase is contacted with the preparation at a pH of 7.0±1.0, and a salt concentration of 10 mM to 200 mM yielding a first fraction, (b) Diafiltering the first fraction by a first tangential flow filtration to obtain a second fraction, (c) Treating the second fraction with DNase, (d) Diafiltering the DNase treated second fraction obtained by step c) by a second tangential flow, (e) filtration to a buffer with pH of 7.0±1.0, and a salt concentration of 10 mM to 20 mM to yield a third fraction, and optionally (f) Concentrating the third fraction by tangential flow filtration before supplemental chromatography.

The present invention relates to a polynucleotide comprising a Complement Factor I (CFI) nucleotide sequence encoding a CFI polypeptide or a fragment thereof. The invention further relates to a viral particle comprising a recombinant genome comprising the polynucleotide of the invention, and a composition comprising the polynucleotide or viral particle of the invention. The invention also relates to methods of using, and uses of, the polynucleotide, viral particle and/or composition of the invention. The invention also relates to methods of using, and uses of, a polynucleotide comprising a CFI nucleotide sequence, a viral particle comprising a recombinant genome comprising the polynucleotide, or a composition comprising the polynucleotide or viral particle.

Provided herein are compositions, methods, and kits for detecting human picobirnavims (PBV). In certain embodiments, provided herein are PBV specific nucleic acid probes and primers, and methods for detecting PBV nucleic acid.

Methods and compositions for treating and/or preventing a bacterial infection in a subject are provided, in which the subject is administered a fecal sample obtained from a donor subject via fecal microbiota transplantation (FMT). The fecal sample contains bacteriophages that target the bacteria causing the infection. In some embodiments, the fecal sample containing the bacteriophages can be obtained from a donor subject who previously had the same infection but is now cured.

Methods and compositions for treating and/or preventing a bacterial infection in a subject are provided, in which the subject is administered a fecal sample obtained from a donor subject via fecal microbiota transplantation (FMT). The fecal sample contains bacteriophages that target the bacteria causing the infection. In some embodiments, the fecal sample containing the bacteriophages can be obtained from a donor subject who previously had the same infection but is now cured.

Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.

Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.